Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab

http://hdl.handle.net/10400.1/12800

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
10.1177_1756284819869141.pdf		910.65 KB	Adobe PDF	Download

Authors

Magro, Fernando

Portela, Francisco

Branquinho, Diogo

Fernandes, Samuel

Cravo, Marília

Caldeira, Paulo

Abstract(s)

Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.

Keywords

Endoscopic activity Golimumab Histological activity Serum soluble ST2 Ulcerative colitis

URI

http://hdl.handle.net/10400.1/12800

Publisher

SAGE Publications

DOI

10.1177/1756284819869141

Collections

FCB2-Artigos (em revistas ou actas indexadas)
ULS2-Artigos (em revistas ou actas indexadas)
ULS_10.1-MED-Artigos

CC License

Altmetrics